for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Assembly Biosciences Inc

ASMB.OQ

Latest Trade

14.11USD

Change

-0.40(-2.76%)

Volume

208,059

Today's Range

13.95

 - 

14.79

52 Week Range

10.62

 - 

38.21

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
14.51
Open
14.65
Volume
208,059
3M AVG Volume
6.04
Today's High
14.79
Today's Low
13.95
52 Week High
38.21
52 Week Low
10.62
Shares Out (MIL)
25.71
Market Cap (MIL)
381.05
Forward P/E
-3.91
Dividend (Yield %)
--

Latest Developments

More

Assembly Biosciences Announces Appointment Of John Mchutchison As President And Chief Executive Officer

Assembly Biosciences Q2 Loss Per Share $0.72

Assembly Biosciences Q1 Loss Per Share $1.05

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Assembly Biosciences Inc

Assembly Biosciences, Inc. is a biotechnology company. The Company is engaged in developing two platform programs, such as a class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection, and a class of oral synthetic live therapeutics, which are designed to restore health to a dysbiotic microbiome. It has discovered various core protein Allosteric Modulators (CpAMs), which are small molecules that directly target and allosterically modulate the HBV core (HBc) protein. Its Microbiome Program consists of an integrated platform that includes a strain identification and selection process, methods for strain isolation and growth under current good manufacturing practice conditions, and a delivery system, GEMICEL, which allows for targeted oral delivery of live biologic and conventional therapies to the lower gastrointestinal (GI) tract. The lead product candidate from this platform, AB-M101, is in development for the treatment of clostridium difficile-infections.

Industry

Biotechnology & Drugs

Contact Info

11711 N Meridian St Ste 310

+1.212.5544388

https://www.assemblybio.com/

Executive Leadership

William R. Ringo

Non-Executive Independent Chairman of the Board

John G. McHutchison

President, Chief Executive Officer, Director

Richard J. Colonno

Executive Vice President, Chief Scientific Officer

Jacqueline Sybil Papkoff

Senior Vice President, Chief Scientific Officer Microbiome

David R. Houck

Senior Vice President - Product Development and Portfolio Management

Key Stats

1.33 mean rating - 6 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2016

-2.570

2017

-2.410

2018

-3.980

2019(E)

-3.792
Price To Earnings (TTM)
--
Price To Sales (TTM)
25.43
Price To Book (MRQ)
2.18
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-53.16
Return on Equity (TTM)
-48.58

Latest News

BRIEF-Assembly Biosciences Q1 Loss Per Share $0.80

* ASSEMBLY BIOSCIENCES ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS

BRIEF-Assembly Biosciences Presents Positive Interim Data from Phase 1a and 1b Studies of ABI-H0731 in HBV Patients

* ASSEMBLY BIOSCIENCES PRESENTS POSITIVE INTERIM DATA FROM PHASE 1A AND 1B STUDIES OF ABI-H0731 IN HBV PATIENTS IN A LATE-BREAKER SESSION AT THE EASL CONFERENCE

BRIEF-Assembly Biosciences Says Graham Cooper Joined Assembly As New CFO And COO Effective March 8​

* ASSEMBLY BIOSCIENCES ANNOUNCES ADDITIONS TO MANAGEMENT TEAM AND BOARD OF DIRECTORS

BRIEF-Assembly Biosciences Files For Mixed Shelf Of Up To $250 Mln

* ASSEMBLY BIOSCIENCES FILES FOR MIXED SHELF OF UP TO $250 MILLION - SEC FILING Source text: (http://bit.ly/2CnCeGR) Further company coverage:

BRIEF-Assembly Biosciences Appoints Sue Mahony To Board Of Directors

* ASSEMBLY BIOSCIENCES APPOINTS SUE MAHONY, PHD TO BOARD OF DIRECTORS

BRIEF-Assembly Biosciences prices public offering of 2.21 mln common shares at $27.25 per share

* Assembly biosciences announces pricing of $60 million offering of common stock

BRIEF-Assembly Biosciences announces successful completion of ABI-h0731 phase 1A trial

* Assembly Biosciences announces successful completion of ABI-H0731 phase 1A trial and upcoming conference presentations

BRIEF-Allergan enters into licensing agreement with Assembly Biosciences

* Will make upfront payment to assembly of $50 million for exclusive, worldwide rights to develop and commercialize UC, CD and IBS compounds

BRIEF-Assembly Biosciences starts Phase 1 program of treatment for Hepatitis B virus infection

* Initiates phase 1 clinical program of abi-h0731 for treatment of chronic hepatitis b virus infection

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up